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Abstract 
Objective: The risk of ischemic stroke, systemic thromboembolism, and all-cause death among 
heart failure patients previously diagnosed with diabetes mellitus is poorly described. We evaluated 
the risk of these endpoints among heart failure patients without diagnosed atrial fibrillation 
according to the presence of diabetes mellitus. 
Methods: Population-based nationwide cohort study of non-anticoagulated patients diagnosed with 
incident heart failure during 2000-2012, identified by record linkage between nationwide registries 
in Denmark. We calculated relative risks after 1 year to evaluate the association between diabetes 
and risk of events in 39,357 heart failure patients, among whom 18.1% had diabetes. Analysis took 
into account competing risks of death. 
Results: Absolute risks of all endpoints were higher in patients with diabetes compared to patients 
without diabetes after 1-year follow-up (ischemic stroke: 4.1% vs. 2.8%; systemic 
thromboembolism: 11.9% vs. 8.6%; all-cause death: 22.1% vs. 21.4%). Diabetes was significantly 
associated with an increased risk of ischemic stroke (adjusted relative risk [RR]: 1.27, 95% 
confidence interval [CI]: 1.07-1.51); systemic thromboembolism (RR: 1.20, 95% CI: 1.11-1.30); 
and all-cause death (RR: 1.17, 95% CI: 1.11-1.23). Additionally, time since diabetes diagnosis was 
associated with higher adjusted cumulative incidences of ischemic stroke, systemic 
thromboembolism, and all-cause death (p for trend, p<0.001). 
Conclusions: Among heart failure patients without atrial fibrillation, diabetes was associated with a 
significantly increased risk of ischemic stroke, systemic thromboembolism, and all-cause death 
compared to those without diabetes, even after adjustment for concomitant cardiovascular risk 
factors. Increased focus on secondary prevention in heart failure patients with diabetes may be 
warranted. 
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Abbreviations: 
AF: Atrial fibrillation 
COPD: Chronic obstructive pulmonary disease 
HF: Heart failure 
TE: Thromboembolic event 
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Introduction  
 
Heart failure (HF) is associated with an increased risk of ischemic stroke and systemic 
thromboembolic events (TE), even without atrial fibrillation (AF)[1,2]. Comorbidities such as 
diabetes mellitus are common in patients with HF[3], and in previous studies of HF patients, 
diabetes has been associated with a higher risk of stroke and systemic TE[4–6]. In addition, 
previous non-HF studies have demonstrated that a longer duration of diabetes influence the risk of 
ischemic stroke[7,8]. A recent study identified insulin-treated diabetes as a predictor of stroke in HF 
patients without AF[9]. However, for the evaluation of possible risk factors for stroke risk 
stratification in patients with HF and without AF, quantifying the association between both presence 
and duration of diabetes and the risk of ischemic stroke, systemic TE, and all-cause death among 
HF patients is an important step. Additionally, this investigation will provide a basis for suggesting 
subgroups of HF patients who might benefit from thromboprophylaxis, as recommended in a recent 
study[10]. This is particularly relevant for HF patients without prior AF who are not traditionally 
considered candidates for thromboprophylaxis. However, assessing predictors of ischemic stroke 
and systemic TE risk in a high-mortality population such as HF patients (5-year mortality of 45-
60%)[11,12] is not trivial because a competing risks setting in which careful consideration of the 
interplay between mortality and ischemic stroke/systemic TE risk is needed to provide meaningful 
risk assessment[13,14]. Thus, any analysis of ischemic stroke and systemic TE in such a high-risk 
population would need to take into account the competing risk of death, although this has not been 
considered in many previous studies of HF populations. 
 
The aim of this study was to prospectively and thoroughly investigate the association between 
diabetes and the risk of ischemic stroke, systemic TE, and all-cause death in patients with incident 
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HF without diagnosed AF (and not taking a vitamin K antagonist to avoid issues with effect 
modification by anticoagulation therapy) to possibly identify a high-risk subgroup which could be 
used in stroke risk stratification in the HF population. We investigated the hypothesis that the 
presence of diabetes in non-anticoagulated incident HF patients without diagnosed AF would be 
associated with a higher risk of adverse events, and second, that this risk would increase with longer 
duration of diagnosed diabetes. 
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Methods 
Registry Data Sources 
We used three different nationwide registries in this study:  i) Danish National Patient Registry[15] 
which has registered all hospital admissions along with diagnoses since 1977 and codes all 
diagnoses according to the 10
th
 revision of the International Classification of Diseases (ICD-10) 
since 1994; ii) The National Prescription Registry[16] which contains data on all prescriptions 
dispensed from Danish pharmacies since 1994, coded according to the Anatomical Therapeutic 
Chemical (ATC) Classification System; iii) The Danish Civil Registration System which holds 
information on date of birth, migration, vital status, date of death, and sex of all persons living in 
Denmark[17]. Data were linked via a unique personal identification number used in all Danish 
national registries. All three registries were up to December 31
st
 2013. These registries have 
previously been well-validated[15,16,18], and the diagnoses of HF, diabetes, AF, and ischemic 
stroke have been found to be valid[18–22]. 
 
Study Population 
The study population was identified as in- or outpatients aged>50 years, discharged with a primary 
diagnosis of incident HF (first-time diagnosis of HF) in the period January 1
st
 2000 - December 31
st
 
2012 (ICD-10: I50, I42.0, I11.0, I13.0, I13.2). Diabetes mellitus was identified using ICD codes or 
a claimed prescription of a glucose-lowering drug (ICD-8: 24900, 24909, 25008, 25009; ICD-10: 
E10, E11.0; ATC: A10). Duration of diabetes was calculated from date of first diagnosis (ICD-8 or 
ICD-10 code), or from the date of first claimed prescription of a glucose-lowering drug, whichever 
came first, until the time of discharge with a diagnosis of HF. To restrict our analysis to patients 
without AF, we excluded those who had a prior diagnosis of AF or atrial flutter (ICD-10: I48) 
between 1994 and date of HF diagnosis. We also excluded patients treated with a vitamin K 
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antagonist (ATC: B01AA03, B01AA04) within six months prior to the HF diagnosis (to avoid 
issues with effect modification by anticoagulation therapy). During our inclusion period, the use of 
non-vitamin K antagonist oral anticoagulants was almost non-existent in the HF population, and 
therefore, not relevant in this study. Patients with a diagnosis of cancer (ICD-10: C00-C97) within 5 
years before HF diagnosis were also excluded, since cancer patients represents a subgroup with 
high stroke risk[23] and specialized thromboprophylactic treatment regimens.  
 
Additional comorbidities at baseline were identified using the Danish National Patient Registry and 
the Danish National Prescription Registry which have registered diagnoses (using ICD-10 codes) 
and prescriptions (using ATC codes) since 1994. Ascertainment of baseline medication status was 
based on medication purchase in a 45-day window before or after the date of HF diagnosis. ICD-
codes and ATC-codes used to define comorbidities and medical therapies are provided in the 
online-only Supplement [see eTable 1 in the Supplementary material]. 
 
Outcomes 
The primary endpoints were defined as an ischemic stroke diagnosis (ICD-10: I63, I64) or a 
diagnosis of a systemic TE (ischemic stroke (ICD-10: I63, I64), transient ischemic attack (ICD-10: 
G45), systemic arterial embolism (ICD-10: I74), or acute myocardial infarction (ICD-10: I21, I23)). 
Because of the high mortality in the HF population, all-cause death (according to The Danish Civil 
Registration System) was also included as a primary endpoint.  
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Statistical Methods  
Baseline characteristics (at time of HF diagnosis) were described separately for patients with and 
without diabetes, using means and standard deviation for continuous measures and proportions for 
categorical measures.  
 
Time-to-event analysis was used to describe the association between diabetes and the risk of 
ischemic stroke, systemic TE, and all-cause death. Time at risk was measured from baseline date 
(date of HF diagnosis) and until an event of ischemic stroke or systemic TE, date of death, 
emigration, or end of study (December 31
st
 2013), whichever came first. Additionally, patients were 
censored if they initiated anticoagulant therapy during the follow-up period.  
 
Absolute risks of all endpoints were estimated based on Aalen-Johansen[24] estimator for 
competing risks data according to presence of diabetes. Regression analysis was used to compare 
the 1-year relative risk of the three endpoints according to presence of diabetes. To this end, we 
used generalized linear regression alongside the pseudo-value method in order to take into account 
the competing risk of death[25,26]. The pseudo-value regression technique reduces to simple 
regression (with a log-link function) on the event status indicator at 1 year in the absence of 
censoring. The associations between diabetes and risk of the three endpoints were presented using 
both crude relative risks and relative risks adjusted for age, sex, and cardiovascular risk factors, 
such as hypertension, vascular disease, renal disease, chronic obstructive pulmonary disease, and 
prior stroke/transient ischemic attack. We repeated these analyses after 5 years of follow-up in the 
Supplementary material. Additionally, we provided the results of each component of the systemic 
thromboembolic end point in the Supplementary material. 
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In a secondary analysis with a more explorative focus, duration of diagnosed diabetes was analyzed 
as a categorical variable (duration of <5 years, 5-10 years, and >10 years). We used an inverse-
probability-weighting approach[27] to calculate adjusted cumulative incidence curves for all 
endpoints (taking into account competing risks)[24] for each duration category. P-values for trend 
were obtained by entering the categorical duration of the diagnosed diabetes variable as a 
continuous ordinal covariate in a linear regression model for the pseudo-values at 1 year, adjusting 
for concomitant risk factors as before. 
 
As a sensitivity analysis, since some patients might be taken glucose-lowering drug due to a pre-
diabetic state, we repeated the main analysis when using only diagnosis codes (ICD-8/ICD-10 
codes) to define patients with diabetes. Furthermore, we performed a similar sensitivity analysis, 
where we defined patients with diabetes only if they had a diagnosis code of diabetes and 
concomitantly had claimed a prescription for a glucose-lowering drug. We also performed a 
sensitivity analysis in which patients with a history of ischemic stroke were excluded (since a prior 
ischemic stroke diagnosis is a strong risk factor for a subsequent stroke)[28]. Additionally, as some 
patients might get a diagnosis of AF shortly after the HF diagnosis, a sensitivity analysis was 
performed by repeating the absolute and relative risk calculations when extending the definition of 
concomitant AF at baseline; presence of a prior diagnosis of AF at baseline or within 30 days after 
HF diagnosis. Furthermore, some patients are diagnosis with AF during follow-up; thus, we 
performed another sensitivity analysis by repeating the absolute and relative risk calculations after 
censoring patients who are diagnosed with AF during follow-up.  
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Analyses were performed using Stata version 13 (Stata Corporation, College Station, TX, USA) and 
R version 3.0.2 (The R Foundation for Statistical Computing). A two-sided p-value of <0.05 was 
considered statistically significant.  
 
Ethical Considerations 
No ethical approval is required for anonymous register studies in Denmark. The study was 
approved by the Danish Data Protection Agency (J. No. File No. 2012-41-0633). 
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Results 
 
The study population comprised 39,357 HF patients aged >50 years, among which 18.1% had 
diabetes [Figure 1]. The median follow-up period with respect to ischemic stroke was 2.5 years 
(interquartile range: 0.6-5.3 years). The baseline characteristics of the study population are 
summarized in Table 1. A history of stroke/transient ischemic attack, systemic TE, myocardial 
infarction, vascular disease, hypertension, and renal disease was more frequent among patients with 
diabetes than in patients without diabetes. Additionally, patients with diabetes were more often on 
statins and antiplatelet therapy. 
 
The absolute risks of all endpoints were higher in patients with diabetes compared to patients 
without diabetes after 1-year follow-up (ischemic stroke: 4.1% vs. 2.8%; systemic TE: 11.9% vs. 
8.6%; all-cause death: 22.1% vs. 21.4%) [Table 2]. After 1-year follow-up, diabetes was 
independently associated with an increased risk of ischemic stroke (adjusted relative risk [RR]: 
1.27, 95% confidence interval [CI]: 1.07-1.51); systemic TE (adjusted RR: 1.20, 95% CI: 1.11-
1.30); and all-cause death (adjusted RR: 1.17, 95% CI: 1.11-1.23) [Table 2]. Similar conclusions 
were obtained after 5-years follow-up [see eTable 8 in the Supplementary material]. When 
examining the individual components of the systemic thromboembolic end point, diabetes was 
associated with an increased risk of myocardial infarction, and for the end point of transient 
ischemic attack and systemic embolism separately, the event numbers were too low to make any 
conclusions [see eTable 9 in the Supplementary material]. 
 
For the secondary exploratory investigation of the association between time since diabetes diagnosis 
and outcomes, Figure 2B and Figure 2C suggest a dose-response relationship between diabetes 
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diagnosis and the cumulative incidences of systemic TE and all-cause death (p for trend; systemic 
TE: p<0.001; all-cause death: p<0.001). For the endpoint of ischemic stroke, a dose-response 
relationship between time since diabetes diagnosis and outcome risk was less clear [Figure 2A] (p 
for trend; ischemic stroke: p<0.001). Raw numerical values for the absolute risks of ischemic 
stroke, systemic TE, and all-cause death after 1-year follow-up, stratified according to duration of 
diabetes, are shown in eTable 7 in the Supplementary material. 
 
In the sensitivity analysis using only ICD-codes to define patients with diabetes, we found similar 
results as in the main analysis [see eTable 2 in the Supplementary material]. Likewise, in the 
sensitivity analysis using ICD-codes in combination with ATC-codes to define patients with 
diabetes, the results were similar to the main analysis [see eTable 6 in the Supplementary material].  
When excluding patients with prior ischemic stroke, the risk of ischemic stroke and systemic TE 
was lower in the whole study population. Diabetes was still associated with an increased risk of 
ischemic stroke, although borderline non-significant. However, for the endpoint of systemic TE and 
death the conclusions remained the same as in the main analysis [see eTable 3 in the 
Supplementary material]. In the sensitivity analysis, repeating the absolute and relative risk 
calculations after extending the definition of concomitant AF, we found very similar results as in 
the main analyses [see eTable 4 in the Supplement]. When censoring patients with HF who are 
diagnosed with AF during follow-up, similar results were found and the conclusions remained the 
same as in the main analysis [see eTable 5 in the Supplement].   
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Discussion 
 
In this large prospective study, we found a higher risk of ischemic stroke, systemic TE, and all-
cause death among HF patients with diabetes compared to HF patients without diabetes after 1-year 
follow-up, and even after extensive adjustment for concomitant cardiovascular risk factors. Second, 
there was a dose-response relationship between time since diabetes diagnosis and the cumulative 
incidences of systemic TE and all-cause death. To our knowledge, this is the first study to 
thoroughly examine diabetes as a risk factor of ischemic stroke/systemic TE and the association 
between duration of diabetes and the end points in a HF population without AF. 
 
Patients with diabetes have altered hemostasis, platelet activity, and vascular endothelial function 
contributing to a prothrombotic state[29]. In our study, patients with diabetes had more 
comorbidities, such as hypertension, vascular disease, prior stroke/systemic TE, and ischemic heart 
disease compared to HF patients without diabetes. All these comorbidities are well-known risk 
factors of ischemic stroke and recurrent stroke. The presence of comorbidities and the 
prothrombotic state might partly explain the link between diabetes and the higher risk of systemic 
TE. However, we emphasize that our study focused on exploring the prognostic value of diabetes in 
relation to systemic thromboembolic risks; we cannot draw conclusions on causality. Furthermore, 
as mentioned, diabetes was associated with an increased risk of ischemic stroke and systemic TE 
even after adjustment for other cardiovascular risk factors which highlight the significance of this 
risk factor in the HF population without AF. 
 
A longer duration of diabetes has previously been demonstrated to be associated with the risk of 
ischemic stroke in the form of a dose-response relationship[7]. Additionally, duration of diabetes is 
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associated with an increased risk of other cardiovascular diseases and cardiovascular 
mortality[30,31]. In our study, we found a dose-response relationship between the time since 
diabetes diagnosis and cumulative incidences of systemic TE and all-cause death. The relationship 
between time since diabetes diagnosis and risk of ischemic stroke, on the other hand, was more 
equivocal, which may be attributed to limitations of the register-based definition of diabetes 
duration (see limitations below).  
 
Clinical Perspectives 
The increasing prevalence of both HF and diabetes highlights the clinical relevance of our findings.  
In this study, diabetes was associated with an increased risk of ischemic stroke and most likely this 
comorbidity will be useful for stroke risk stratification in HF patients without AF. However, 
patients with diabetes are a very heterogeneous group with varying degrees of diabetes duration, 
glycemic control, and diabetic complications; thus, it may be necessary to subdivide these patients 
according to severity of diabetes for optimal risk stratification. Whether duration of diabetes will 
enhance the identification of high-risk HF patients need to be further examined in future studies. 
 
Currently, patients with HF and without AF are not routinely recommended antiplatelet or 
anticoagulant therapy[32]. HF patients with diabetes have an increased risk of various 
thromboembolic diseases and may represent a high-risk subgroup of HF patients without AF that 
could potentially benefit from intensive thromboprophylaxis. However, this speculation would need 
further examination in future studies.  
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Strengths and Limitations   
The major strengths of this study are the validated outcomes and large sample size uniquely 
possible with this type of cohort study. Selection into the study was not an issue, since we 
investigated a nationwide population cohort of incident HF patients without AF, with limited loss to 
follow-up. We also accounted for the competing risk of death, an important issue when 
investigating risk predictors in populations with high mortality[14,33]. 
The study also has some important limitations. We were unable to distinguish between HF with 
preserved and reduced ejection fraction or estimate the functional classification, since we did not 
have access to echocardiograms. Whether the prevalence of stroke differs in patients with preserved 
and reduced ejection fraction is currently unknown due to inconsistent results[5,34–36]. However, 
no difference in embolic risk (risk of stroke, transient ischemic stroke, or systemic embolism) was 
found in a recent study of non-anticoagulated HF patients with reduced and preserved ejection 
fraction[34]. Similarly, in a post-hoc analysis of a study of AF patients with HF with reduced or 
preserved ejection fraction, no difference in ischemic stroke risk was found between the groups[35]. 
On the other hand, the functional classification among patients with HF would also vary over time 
and with treatments.  
The diagnosis of HF has previously been validated with a sensitivity of 29%, a specificity of 99%, 
and a positive predictive value of 81-100%[20,21]; thus, we did not capture all patients with HF and 
also cannot be certain that all patients identified as having HF had definite HF, which could lead to 
imprecision in the risk estimates. In addition, we cannot rule out that some patients without AF 
might have had undiagnosed AF, since heart disease is associated with an increased risk of 
developing AF and AF is ‘silent’ in up to a quarter of patients; however, in the sensitivity analysis, 
where patients were censored if they developed AF during follow-up, the conclusions remained the 
same as in the main analysis.  
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We only included patients aged >50 years, as HF in persons aged <50 years might represent a 
different group of patients, for example patients with congenital heart disease. Accordingly, our 
findings may not apply to younger HF patients. Additionally, our study population was ethnically 
non-diverse, since we investigated a Danish HF population. Thus, our study results might not be 
generalizable to more diverse HF populations. 
Patients with diabetes but without a hospital-based diagnosis of diabetes and treated only non-
pharmacologically were not included in this study, thus, our population is unlikely to include 
patient groups with a reversible state of diabetes. This may explain the lower prevalence of diabetes 
(18%) in our cohort compared to other HF cohorts (approximately 30%)[9,37]. Moreover, we were 
not able to distinguish between type 1 and type 2 diabetes which would be a very relevant 
separation.  
We did not have access to information regarding smoking habits, body mass index, and lipid profile 
which we recognized as important factors when investigating diabetes and ischemic stroke risk. 
However, since the focus was on the prognostic value of a diabetes diagnosis, not its causal role, 
confounding by possible stroke risk factors is not an issue of concern in this study. We investigated 
whether the presence of diabetes was associated with ischemic stroke, systemic TE, and death in 
patients with HF, and therefore, we adjusted for well-known cardiovascular risk factors for stroke. 
This was not an attempt to adjust for confounding and hereby explore the potential causal 
relationship between the exposure and outcomes, but to elucidate the potential predictive ability of 
the exposure to risk stratification in patients with HF, after adjustment for other possible risk 
factors. 
In the secondary, exploratory analysis we calculated the duration of diabetes as the time from first 
diagnosis with an ICD-8/ICD-10 code or from the first claimed prescription of a glucose-lowering 
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drug, whichever came first, until the time of discharge with a diagnosis of HF. This register-based 
proxy for the duration of diabetes has important limitations; it can be affected by delayed diagnosis, 
changes over time in diagnostic criteria, and changes over time in medical treatment. Due to these 
limitations, we examined the association between duration of diabetes and risk of events as a 
secondary, explorative analysis. The above-mentioned limitations could explain the less clear dose-
response relationship between time since diabetes diagnosis and the cumulative incidence of 
ischemic stroke.  
Finally, the diagnosis of ischemic stroke was defined by the Danish Hospital Discharge Register, 
and not all stroke endpoints have been defined by cerebral imaging, and thus, the data did not allow 
classification of various ischemic stroke types. We included unspecified stroke (ICD-10: I64) in the 
definition of ischemic stroke, as most strokes are of ischemic origin. However, we cannot rule out 
that some of these strokes might have been hemorrhagic strokes and thus, misclassified as ischemic 
strokes. Nonetheless, the ischemic stroke diagnosis has previously been validated[18]. 
In conclusion, diabetes was associated with a significantly higher risk of ischemic stroke, systemic 
TE, and all-cause death in HF patients without AF, which persisted after adjustment for 
concomitant cardiovascular risk factors, and longer time since diabetes diagnosis was associated 
with higher risks.  
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Titles and Legends to Figures 
 
Figure 1: Flowchart of patients included in the final study population.  
Figure 2: Adjusted cumulative incidence curve of the three endpoints according to duration of 
diagnosed diabetes. A) Adjusted cumulative incidence curve of ischemic stroke; B) Adjusted 
cumulative incidence curve of any systemic thromboembolic event; C) Adjusted cumulative 
incidence curve of all-cause death. 
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 Table 1. Baseline characteristics of study population, stratified according to presence of diabetes. 
  
  
 
 
Clinical characteristics No diabetes Diabetes 
 
N, % (n) 81.9 (32,249) 18.1 (7,108) 
 
 
Sex (females), % (n) 45.7 (14,722) 38.3 (2,723) 
 
Mean age at baseline, years (SD) 74.5  (11.5)  72.1 (10.5) 
 
 
Baseline comorbidity, % (n)  
 
 
Previous any stroke/TIA 12.0 (3,884)  17.1 (1,215) 
 Previous myocardial infarction 24.0 (7,723) 29.8 (2,118) 
 Previous systemic  thromboembolism* 32.3 (10,415) 41.2 (2,929) 
 Vascular disease 29.8 (9,608) 39.8 (2,828) 
 Hypertension 27.4 (8,827)  49.8 (3,541) 
 
Renal Disease 4.6 (1,492)  8.5 (605) 
 
Liver Disease 0.4 (127) 0.7 (49) 
 
Hyperthyroidism 2.6 (830) 2.7 (191) 
 
COPD 13.2 (4,254) 13.9 (989) 
 
  
Baseline medication, % (n)  
 
 
ACE-inhibitors 50.4 (16,245) 55.4 (3,941) 
 
Angiotensin receptor blocker 9.0 (2,915) 16.9 (1,200) 
 Beta-blockers 42.8 (13,808) 48.2 (3,424) 
 
Aldosterone antagonists 22.1 (7,119) 27.1 (1,923) 
 
Non-loop diuretics 37.8 (12,194) 43.8 (3,113) 
 
Loop diuretics 63.7 (20,548) 73.0 (5,185) 
 
Statins 27.6 (8,912) 44.9 (3,189) 
 
NSAIDs 13.9 (4,473) 14.8 (1,053) 
 
Aspirin 46.4 (14,973) 54.3 (3,859) 
 
Thienopyridines 10.3 (3,332) 13.2 (941) 
 
Insulins and analogues - 28.2 (2,003) 
 
Blood glucose lowering drugs - 54.7 (3,890) 
 
 
Abbreviations: COPD= Chronic obstructive pulmonary disease; NSAIDs= Non-
steroidal anti-inflammatory drugs; SD=Standard deviation; TIA=Transient 
ischemic attack. 
 
* Composite endpoint of ischemic stroke, transient ischemic attack, systemic 
embolism, acute myocardial infarction. 
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Table 2. Absolute and relative risks of ischemic stroke, systemic thromboembolism, and all-cause 
death after 1-year follow-up, stratified according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
No. of patients 39,357 32,249 7,108 
ISCHEMIC STROKE    
 Event number 1,116 839 277 
 Absolute risk, % 3.0 2.8 4.1 
 Crude relative risk - 1.00 (ref.) 1.49 (1.30-1.70) 
 Adjusted relative risk* - 1.00 (ref.) 1.27 (1.07-1.51) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,473 2,659 814 
 Absolute risk, % 9.9 8.6 11.9 
 Crude relative risk - 1.00 (ref.) 1.38 (1.28-1.49) 
 Adjusted relative risk* - 1.00 (ref.) 1.20 (1.11-1.30) 
ALL-CAUSE DEATH 
   
 Event number 7,980 6,499 1,481 
 Absolute risk, % 21.5 21.4 22.1 
 Crude relative risk - 1.00 (ref.) 1.03 (0.98-1.08) 
 Adjusted relative risk* - 1.00 (ref.) 1.17 (1.11-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease 
(binary), previous stroke/transient ischemic attack (binary), chronic obstructive 
pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic 
embolism, acute myocardial infarction 
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Supplementary materials 
 
eTable 1. ICD10-codes and ATC-codes used in the study.  
eTable 2. Sensitivity analysis (using only diagnosis codes in diabetes definition): Absolute 
and relative risks of ischemic stroke, systemic thromboembolic event, and all-cause death 
after 1-years follow-up, according to presence of diabetes. 
eTable 3. Sensitivity analysis (excluding patients with prior stroke): Absolute and relative 
risks of ischemic stroke, systemic thromboembolic event, and all-cause death after 1-year 
follow-up, according to presence of diabetes. 
eTable 4. Sensitivity analysis (excluding patients with an AF diagnosis within 30 days after 
the HF diagnosis): Absolute and relative risks of ischemic stroke, systemic 
thromboembolic event, and all-cause death after 1-year follow-up, according to presence 
of diabetes. 
eTable 5. Sensitivity analysis (censoring patients developing AF during follow-up): 
Absolute and relative risks of ischemic stroke, systemic thromboembolic event, and all-
cause death after 1-year follow-up, according to presence of diabetes. 
eTable 6. Sensitivity analysis (using the combination of diagnosis codes and ATC-codes in 
diabetes definition): Absolute and relative risks of ischemic stroke, systemic 
thromboembolic event, and all-cause death after 1-year follow-up, according to presence 
of diabetes. 
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eTable 7. Figure 2 – raw numerical values: Absolute risks of ischemic stroke, systemic 
thromboembolism, and all-cause death after 1-year follow-up, stratified according to 
duration of diabetes. 
eTable 8. Absolute and relative risks of ischemic stroke, systemic thromboembolic event, 
and all-cause death after 5-years follow-up, according to presence of diabetes. 
eTable 9. Absolute risks of each component of the systemic thromboembolic end point 
(besides ischemic stroke) after 1-year follow-up, stratified according to duration of 
diabetes. 
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eTable 1. ICD-10 codes and ATC-codes used in the study. 
ICD 10-Codes and ATC-Codes used in the Study 
 Main diagnosis ICD 10-Codes 
Congestive heart failure I50.0-I50.9, I11.0, I13.0, I13.2 
Diabetes mellitus E10.0-E10.9, E11.0-E11.9 + (24900, 24909, 25008, 25009 (ICD-8)) + (ATC: A10) 
Endpoints ICD 10-Codes 
Stroke (ischemic) I63.0-I63.9, I64 
Ischemic stroke (Systemic 
thromboembolic event) 
I63.0-I63.9, I64 
Transient ischemic attack (Systemic 
thromboembolic event) 
G45.0-G45.9 (Not inclusive G45.3 (Amaurosis fugax)) 
Systemic embolism (Systemic 
thromboembolic event) 
I74.0-I74.9 
Acute myocardial infarction (Systemic 
thromboembolic event) 
I21.0-I21.9, I23.0-I23.9 
Comorbidities ICD 10-Codes 
Prior stroke (ischemic or hemorrhagic) I60.0-I60.9, I61.0-I61.9, I62.0-I62.9, I63.0-I63.9, I64.9 
Acute myocardial infarction I21.0-I21.9, I23.0-I23.9 
Vascular disease I21.0-I21.9, I23.0-I23.9, I70.0, I70.2-I70.9, I71.0-I71.9, I73.9 
Hypertension I10.0-I10.9, I11.0-I11.9, I12.0-I12.9, I13.0-I13.9, I15.0–I15.9 
Renal disease 
I12.0-I12.9, I13.0-I13.9, N00-N07, N11.0-N11.9, N14.0-N14.4, N17.0-N17.9, N18.0-
N18.9, N19, Q61.0-Q61.9 
Liver disease 
B15.0-B15.9, B16.0-B16.9, B17.0-B17.9, B18.0-B18.9, B19.0-B19.9, K70.4, K72.0-
K72.9, K76.6 
Hyperthyroidisme E05.0-E05.9, E06.0-E06.9 
Chronic obstructive pulmonary disease 
(COPD) 
J44.0-J44.9 
Atrial fibrillation and flutter (exclusion 
criteria) 
I48 
Cancer any type (exclusion criteria) C00-C97 
Concomitant medication ATC-Codes 
Warfarin (exclusion criteria) B01AA03 
Phenprocoumon (exclusion criteria) B01AA04 
Glucose-lowering medication A10 
ACE-inhibitors C09AA 
Angiotensin receptor blockers C09CA 
Beta-blockers C07 
Non-loop diuretics 
C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G,C09BA, 
C09DA, C09XA52  
Aldosterone antagonists C03DA 
Loop diuretics C03C 
Statins C10 
Non steroidal anti-inflammatory drugs 
(NSAIDs) 
M01A 
Aspirin B01AC06 
Thienopyridines B01AC04, B01AC22, B01AC24 
Insulins and analogous A10A 
Blood glucose lowering drugs A10B 
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eTable 2. Sensitivity analysis (using only diagnosis codes in diabetes definition): Absolute 
and relative risks of ischemic stroke, systemic thromboembolic event, and all-cause death 
after 1-year follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,116 891 225 
 Absolute risk, % 3.0 2.8 4.3 
 Crude relative risk - 1.00 (ref.) 1.53 (1.32-1.77) 
 Adjusted relative risk* - 1.00 (ref.) 1.29 (1.08-1.54) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,757 3,065 692 
 Absolute risk, % 9.9 9.5 13.0 
 Crude relative risk - 1.00 (ref.) 1.37 (1.27-1.48) 
 Adjusted relative risk* - 1.00 (ref.) 1.18 (1.09-1.28) 
ALL-CAUSE DEATH 
   
 Event number 7,980 6,830 1,150 
 Absolute risk, % 21.5 21.4 22.0 
 Crude relative risk - 1.00 (ref.) 1.03 (0.97-1.09) 
 Adjusted relative risk* - 1.00 (ref.) 1.17 (1.10-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
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eTable 3. Sensitivity analysis (excluding patients with prior ischemic stroke): Absolute and 
relative risks of ischemic stroke, systemic thromboembolic event, and all-cause death after 
1-year follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 722 569 153 
 Absolute risk, % 2.1 2.0 2.6 
 Crude relative risk - 1.00 (ref.) 1.28 (1.07-1.53) 
 Adjusted relative risk* - 1.00 (ref.) 1.19 (0.98-1.45) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 2,835 2,235 600 
 Absolute risk, % 8.3 7.9 10.1 
 Crude relative risk - 1.00 (ref.) 1.28 (1.17-1.39) 
 Adjusted relative risk* - 1.00 (ref.) 1.12 (1.02-1.23) 
ALL-CAUSE DEATH 
   
 Event number 6,929 5,715 1,214 
 Absolute risk, % 20.5 20.5 20.7 
 Crude relative risk - 1.00 (ref.) 1.01 (0.96-1.07) 
 Adjusted relative risk* - 1.00 (ref.) 1.16 (1.10-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), chronic obstructive 
pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
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eTable 4. Sensitivity analysis (excluding patients with an AF diagnosis within 30 days after 
the HF diagnosis): Absolute and relative risks of ischemic stroke, systemic 
thromboembolic event, and all-cause death after 1-year follow-up, according to presence 
of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,063 794 269 
 Absolute risk, % 2.9 2.6 4.0 
 Crude relative risk - 1.00 (ref.) 1.52 (1.32-1.74) 
 Adjusted relative risk* - 1.00 (ref.) 1.30 (1.09-1.54) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,327 2,540 787 
 Absolute risk, % 9.0 8.4 11.7 
 Crude relative risk - 1.00 (ref.) 1.39 (1.29-1.50) 
 Adjusted relative risk* - 1.00 (ref.) 1.21 (1.11-1.31) 
ALL-CAUSE DEATH 
   
 Event number 7,817 6,359 1,458 
 Absolute risk, % 21.4 21.3 22.0 
 Crude relative risk - 1.00 (ref.) 1.03 (0.98-1.09) 
 Adjusted relative risk* - 1.00 (ref.) 1.17 (1.11-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
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eTable 5. Sensitivity analysis (censoring patients developing AF during follow-up): 
Absolute and relative risks of ischemic stroke, systemic thromboembolic event, and all-
cause death after 1-year follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,061 788 273 
 Absolute risk, % 2.9 2.6 4.1 
 Crude relative risk - 1.00 (ref.) 1.55 (1.36-1.78) 
 Adjusted relative risk* - 1.00 (ref.) 1.33 (1.11-1.58) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,377 2,579 798 
 Absolute risk, % 9.1 8.5 11.9 
 Crude relative risk - 1.00 (ref.) 1.39 (1.29-1.50) 
 Adjusted relative risk* - 1.00 (ref.) 1.21 (1.12-1.32) 
ALL-CAUSE DEATH 
   
 Event number 7,566 6,147 1,419 
 Absolute risk, % 20.8 20.7 21.5 
 Crude relative risk - 1.00 (ref.) 1.04 (0.99-1.10) 
 Adjusted relative risk* - 1.00 (ref.) 1.18 (1.12-1.24) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
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eTable 6. Sensitivity analysis (using the combination of diagnosis codes and ATC-codes in 
diabetes definition): Absolute and relative risks of ischemic stroke, systemic 
thromboembolic event, and all-cause death after 1-year follow-up, according to presence 
of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,116 934 182 
 Absolute risk, % 3.0 2.8 4.3 
 Crude relative risk - 1.00 (ref.) 1.51 (1.29-1.76) 
 Adjusted relative risk* - 1.00 (ref.) 1.28 (1.06-1.54) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,473 2,937 536 
 Absolute risk, % 9.2 8.8 12.5 
 Crude relative risk - 1.00 (ref.) 1.42 (1.30-1.54) 
 Adjusted relative risk* - 1.00 (ref.) 1.18 (1.08-1.30) 
ALL-CAUSE DEATH 
   
 Event number 7,980 7,051 929 
 Absolute risk, % 21.5 21.5 22.1 
 Crude relative risk - 1.00 (ref.) 1.03 (0.97-1.09) 
 Adjusted relative risk* - 1.00 (ref.) 1.21 (1.14-1.28) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
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eTable 7. Figure 2 – raw numerical values: Absolute risks of ischemic stroke, systemic 
thromboembolism, and all-cause death after 1-year follow-up, stratified according to 
duration of diabetes. 
 
Duration of diabetes <5 years 5-10 years >10 years 
 
Absolute risk, % (95% CI) 
    
Ischemic stroke 3.6 (2.8-4.3) 4.3 (3.5-5.2) 4.5 (3.6-5.4) 
Systemic thromboembolism 11.0 (9.8-12.2) 11.3 (9.9-12.6) 13.7 (12.2-15.2) 
All-cause death 19.6 (18.1-21.2) 22.9 (21.0-24.7) 24.3 (22.4-26.2) 
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eTable 8. Absolute and relative risks of ischemic stroke, systemic thromboembolic event, 
and all-cause death after 5-years follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 2,421 1,845 576 
 Absolute risk, % 7.3 6.8 9.6 
 Crude relative risk - 1.00 (ref.) 1.42 (1.30-1.55) 
 Adjusted relative risk* - 1.00 (ref.) 1.23 (1.10-1.36) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 6,193 4,751 1,442 
 Absolute risk, % 18.1 16.9 23.3 
 Crude relative risk - 1.00 (ref.) 1.38 (1.31-1.46) 
 Adjusted relative risk* - 1.00 (ref.) 1.20 (1.14-1.27) 
ALL-CAUSE DEATH 
   
 Event number 15,638 12,665 2,973 
 Absolute risk, % 48.7 47.8 52.4 
 Crude relative risk - 1.00 (ref.) 1.10 (1.06-1.13) 
 Adjusted relative risk* - 1.00 (ref.) 1.16 (1.14-1.19) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
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eTable 9. Absolute risks of each component of the systemic thromboembolic end point 
(besides ischemic stroke) after 1-year follow-up, stratified according to duration of 
diabetes. 
Endpoint  Overall No diabetes Diabetes 
TRANSIENT ISCHEMIC ATTACK 
   
 Event number 226 184 42 
 Absolute risk, % 0.6 0.6 0.6 
 Crude relative risk - 1.00 (ref.) 1.02 (0.73-1.43) 
 Adjusted relative risk* - 1.00 (ref.) 0.83 (0.52-1.33) 
SYSTEMIC EMBOLISM 
   
 Event number 67 49 18 
 Absolute risk, % 0.2 0.2 0.3 
 Crude relative risk - 1.00 (ref.) 1.65 (0.96-2.84) 
 Adjusted relative risk* - 1.00 (ref.) 1.42 (0.65-3.13) 
ACUTE MYOCARDIAL INFARCTION 
   
 Event number 2,268 1,739 529 
 Absolute risk, % 6.0 5.6 7.7 
 Crude relative risk - 1.00 (ref.) 1.37 (1.25-1.51) 
 Adjusted relative risk* - 1.00 (ref.) 1.15 (1.03-1.27) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary).  
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FIGURE 1  
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FIGURE 2 
